Calcium and Vitamin D Supplementation with 3-year Denosumab Treatment is Beneficial to Enhance Bone Mineral Density in Postmenopausal Patients with Osteoporosis and Rheumatoid Arthritis

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2018 Dec 28

PMID 30588001

Citations 4

Authors

Takako Suzuki

Yukio Nakamura

Hiroyuki Kato

Affiliations

Soon will be listed here.

Abstract

Background: This 3-year retrospective study compared the outcomes of bisphosphonate-pretreated denosumab therapy with or without vitamin D and calcium supplementation in postmenopausal osteoporosis (OP) patients with rheumatoid arthritis (RA).

Materials And Methods: Fifty-eight patients under long-term denosumab treatment were divided into groups without (denosumab group; 31 cases) or with (combination group; 27 cases) vitamin D and calcium supplementation. The bone markers of BAP, TRACP-5b, and urinary NTX were measured at baseline and every year for 3 years. We also evaluated bone mineral density (BMD) of the lumbar 1-4 vertebrae (L-BMD) and bilateral total hips (H-BMD) at the same time points.

Results: There were no significant differences in the percent changes of serum albumin-corrected calcium between the groups. The percent change in TRACP-5b was significantly higher in the combination group at 2 years. Serum 25-hydroxyvitamin D status was persistently high during therapy in both groups, with significant percent increases over baseline at 2 and 6 months in both groups and at 24 months in the combination group. The percent increase from baseline of serum zinc was significantly higher at 3 years in the combination group over the denosumab group. L-BMD and H-BMD were significantly increased at every time point for 3 years vs pretreatment levels in both groups and were significantly higher in the combination group at all time points.

Conclusion: Compared with denosumab monotherapy, the combination group displayed significantly increased serum zinc, L-BMD, and H-BMD at 3 years in OP patients with RA. Thus, calcium and vitamin D supplementation may be beneficial to enhance BMD gains, but not necessarily 25-hydroxyvitamin D status, in patients with OP and RA under denosumab.

Citing Articles

Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults.

Grygorieva N, Tronko M, Kovalenko V, Komisarenko S, Tatarchuk T, Dedukh N Nutrients. 2024; 16(2).

PMID: 38257163 PMC: 10820145. DOI: 10.3390/nu16020270.

Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis.

Yagita M, Morita T, Kumanogoh A Rheumatol Adv Pract. 2022; 5(3):rkab099.

PMID: 34988358 PMC: 8693364. DOI: 10.1093/rap/rkab099.

The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis.

Wu J, Dong J, Li S, Luo J, Zhang Y, Liu H Front Med (Lausanne). 2020; 7:312.

PMID: 32766259 PMC: 7381115. DOI: 10.3389/fmed.2020.00312.

Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide.

Raterman H, Lems W Drugs Aging. 2019; 36(12):1061-1072.

PMID: 31541358 PMC: 6884430. DOI: 10.1007/s40266-019-00714-4.

References

Haugeberg G, Uhlig T, Falch J, Halse J, Kvien T . Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000; 43(3):522-30. DOI: 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y. View

Kvien T, Haugeberg G, Uhlig T, Falch J, Halse J, Lems W . Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. Ann Rheum Dis. 2000; 59(10):805-11. PMC: 1753011. DOI: 10.1136/ard.59.10.805. View

Lodder M, Haugeberg G, Lems W, Uhlig T, Orstavik R, Kostense P . Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum. 2003; 49(2):209-15. DOI: 10.1002/art.10996. View

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

van der Linden M, Knevel R, Huizinga T, van der Helm-van Mil A . Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum. 2010; 63(1):37-42. DOI: 10.1002/art.30100. View

Black D, Bauer D, Schwartz A, Cummings S, Rosen C . Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?. N Engl J Med. 2012; 366(22):2051-3. PMC: 4015798. DOI: 10.1056/NEJMp1202623. View

Dimitroulas T, Nikas S, Trontzas P, Kitas G . Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev. 2013; 12(10):958-66. DOI: 10.1016/j.autrev.2013.03.015. View

Roux C, Binkley N, Boonen S, Kiel D, Ralston S, Reginster J . Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 2013; 94(2):153-7. DOI: 10.1007/s00223-013-9763-1. View

10.

Sims N, Martin T . Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 2014; 3:481. PMC: 3899560. DOI: 10.1038/bonekey.2013.215. View

11.

Soen S . [Diagnostic criteria for primary osteoporosis : year 2012 revision]. Clin Calcium. 2014; 24(3):323-9. DOI: CliCa1403323329. View

12.

Morris H . Vitamin D activities for health outcomes. Ann Lab Med. 2014; 34(3):181-6. PMC: 3999315. DOI: 10.3343/alm.2014.34.3.181. View

13.

Ebeling P . Vitamin D and bone health: Epidemiologic studies. Bonekey Rep. 2014; 3:511. PMC: 4015454. DOI: 10.1038/bonekey.2014.6. View

14.

Lips P, Gielen E, van Schoor N . Vitamin D supplements with or without calcium to prevent fractures. Bonekey Rep. 2014; 3:512. PMC: 4015453. DOI: 10.1038/bonekey.2014.7. View

15.

Nakamura Y, Kamimura M, Ikegami S, Mukaiyama K, Uchiyama S, Taguchi A . Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study. BMC Endocr Disord. 2015; 15:81. PMC: 4678608. DOI: 10.1186/s12902-015-0077-3. View

16.

Wintermeyer E, Ihle C, Ehnert S, Stockle U, Ochs G, de Zwart P . Crucial Role of Vitamin D in the Musculoskeletal System. Nutrients. 2016; 8(6). PMC: 4924160. DOI: 10.3390/nu8060319. View

17.

Khashayar P, Aghaei Meybodi H, Rezai Hemami M, Keshtkar A, Dimai H, Larijani B . Vitamin D status and its relationship with bone mineral density in a healthy Iranian population. Rev Bras Ortop. 2016; 51(4):454-8. PMC: 4974161. DOI: 10.1016/j.rboe.2015.09.011. View

18.

Kharroubi A, Saba E, Smoom R, Bader K, Darwish H . Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women. Arch Osteoporos. 2017; 12(1):13. PMC: 5266783. DOI: 10.1007/s11657-017-0306-7. View

19.

Wong T, Das Gupta E, Radhakrishnan A, Gun S, Chembalingam G, Yeap S . Effects of 25-hydroxyvitamin D and vitamin D-binding protein on bone mineral density and disease activity in Malaysian patients with rheumatoid arthritis. Int J Rheum Dis. 2017; 21(5):992-1000. DOI: 10.1111/1756-185X.13048. View

20.

Kamimura M, Uchiyama S, Nakamura Y, Ikegami S, Mukaiyama K, Kato H . Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D and alters values of parathyroid hormone, pentosidine, and bone metabolic markers. Ther Clin Risk Manag. 2017; 13:161-168. PMC: 5315201. DOI: 10.2147/TCRM.S120749. View